Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Oral Pirfenidone in Pulmonary Fibrosis
NCT00080223Phase 2Completed
- Sponsor
- Genentech
- Start
- Aug 2003
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfenidone in idiopathic pulmonary fibrosis (IPF), sponsored by Genentech. Started Aug 2003; status: completed.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00080223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080223.